spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  RESTASIS 

 HSMN NewsFeed - 6 Jul 2021
Viracta Therapeutics Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer and Key Additions to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Mar 2020
Primmune Therapeutics Raises $7 Million Seed Financing to Develop Novel Oral TLR7 Immunotherapies for Cancer and Acute Viral Diseases
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 17 Jan 2020
SkinMedica(R) Launches New Instant Bright Eye Cream For Immediate, Visible Results
Biopharmaceuticals Dermatology Product Launch
 HSMN NewsFeed - 18 Nov 2019
Allergan(R) Announces First Annual National BOTOX(R) Cosmetic (onabotulinumtoxinA) Day
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 11 Nov 2019
Allergan Receives FDA Qualified Infectious Disease Product (QIDP) Designation And Fast Track Designation For ATM-AVI (Aztreonam And Avibactam) For Antibiotic-Resistant Gram-Negative Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Oct 2019
FDA Approves BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Sep 2019
Allergan Receives FDA Approval of Juvéderm VOLUMA(R) XC For Mid-Face Injection Via Cannula
Biopharmaceuticals Devices Dermatology FDA
 HSMN NewsFeed - 30 Aug 2019
Allergan Announces Settlement with Two Ohio Plaintiffs in Federal Opioid Litigation
Biopharmaceuticals Litigation
 HSMN NewsFeed - 24 Jul 2019
Allergan Voluntarily Recalls BIOCELL(R) Textured Breast Implants and Tissue Expanders
Devices Product Recall
 HSMN NewsFeed - 17 Jul 2019
U.S. FDA Accepts Allergan's New Drug Application for Bimatoprost Sustained-Release in Patients with Open-Angle Glaucoma or Ocular Hypertension
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 24 Jun 2019
Allergan Receives FDA Clearance For CoolTone(TM) Device
Devices Dermatology FDA
 HSMN NewsFeed - 21 Jun 2019
FDA Approves BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Mar 2019
Allergan Announces FDA Approval of AVYCAZ(R) (ceftazidime and avibactam) for Pediatric Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Mar 2019
Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Mar 2019
FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Nov 2018
Allergan Makes New Appointments to Finance Leadership Team
Biopharmaceuticals Ophthalmology Dermatology Personnel
 HSMN NewsFeed - 16 Oct 2018
FDA Approves Medicines360's sNDA for LILETTA(R) (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 4 Oct 2018
Allergan Receives FDA Clearance To Treat Area Below The Jawline With CoolSculpting(R)
Devices Dermatology FDA
 HSMN NewsFeed - 8 Aug 2018
Allergan Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board of Directors as Part of Active Board Refreshment Process
Biopharmaceuticals Ophthalmology Dermatology Personnel
 HSMN NewsFeed - 23 Jul 2018
Allergan Receives FDA Fast Track Designation for AGN-241751 for the Treatment of Major Depressive Disorder (MDD)
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Jun 2018
Allergan Continues Active Board Refreshment Process
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Mar 2018
Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin(R)) For The Treatment Of Three Types Of Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 2 Feb 2018
FDA Approves AVYCAZ(R) (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Dec 2017
Allergan Receives FDA Clearance For the CoolSculpting(R) Treatment To Improve Appearance Of Lax Tissue In The Double Chin
Devices Dermatology FDA
 HSMN NewsFeed - 19 Oct 2017
Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis(R)
Biopharmaceuticals Ophthalmology Product Launch
 HSMN NewsFeed - 22 Mar 2017
Allergan Announces Availability of RESTASIS MULTIDOSE(TM) (Cyclosporine Ophthalmic Emulsion) 0.05% -- the First FDA-Approved Preservative Free Prescription Eye Drop Available in a Multidose Bottle
Biopharmaceuticals Ophthalmology Product Launch
 HSMN NewsFeed - 28 Oct 2016
Allergan Introduces RESTASIS MULTIDOSE(TM) (Cyclosporine Ophthalmic Emulsion) 0.05%, a New Delivery System for the One and Only FDA Approved Treatment to Help Patients Produce More of Their Own Tears
Biopharmaceuticals Ophthalmology FDA Product Launch
 HSMN NewsFeed - 16 May 2016
Allergan Announces Positive Pivotal Trial Results for Oculeve Intranasal Tear Neurostimulator
Devices Ophthalmology
 HSMN NewsFeed - 10 Mar 2016
Allergan Receives Complete Response Letter from FDA for Prior Approval Supplement for RESTASIS(R) (Cyclosporine Ophthalmic Emulsion) 0.05% Multi-Dose Preservative-Free Bottle
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 16 Dec 2014
Novartis gains FDA approval for Signifor(R) LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Sep 2013
Neurotech Pharmaceuticals Adds Ophthalmic Leaders to Advance Groundbreaking Sight-Saving Therapies
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 21 Mar 2012
Jerry St. Peter appointed Executive Vice President and General Manager of NicOx Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Apr 2011
Merck to Acquire Inspire Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 17 Feb 2011
Inspire Announces Corporate Restructuring and Strategic Focus on Eye Care Business
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 3 Jan 2011
Inspire Announces Results of Second Phase 3 Trial with Denufosol for Cystic Fibrosis
Biopharmaceuticals
 HSMN NewsFeed - 13 Dec 2010
Inspire Announces Launch of DIQUASTM by Santen in Japan
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 Sep 2010
Inspire Names Robert Savel as Senior Vice President and Chief Technical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Aug 2010
Inspire Names Dr. Charles Johnson as Executive Vice President of Research and Development and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Apr 2010
Inspire Appoints Andrew Koven as Executive Vice President and Chief Administrative and Legal Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Mar 2010
Inspire Elects George Abercrombie to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Feb 2010
Inspire Names Adrian Adams as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Nov 2009
Inspire Completes Patient Enrollment in Three Late-Stage Clinical Trials in Cystic Fibrosis, Dry Eye and Blepharitis
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 6 Jun 2008
Inspire Announces Achievement of Primary Endpoint in Phase 3 Trial with Denufosol for Cystic Fibrosis
Biopharmaceuticals
 HSMN NewsFeed - 14 Jan 2008
Inspire Announces Its Termination of Bilastine Licensing Agreement
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Aug 2007
InSite Vision Announces U.S. Launch of AzaSite(TM) for Ocular Infections
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 13 Aug 2007
Inspire Pharmaceuticals Launches AzaSite(TM) in the United States for Ocular Infections
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 20 Jun 2007
Inspire and FAES Farma Amend Bilastine Licensing Agreement
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Jun 2007
Inspire Adds Stephen D. Celestini as Senior Vice President and Chief Compliance Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Apr 2007
Inspire Announces FDA Approval Of AzaSite(TM)
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 20 Feb 2007
Inspire Announces Executive Management Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Feb 2007
Inspire Licenses AzaSite(TM) For Ocular Infections
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 16 Jan 2007
Inspire Provides Cystic Fibrosis Clinical Program Update
Biopharmaceuticals
 HSMN NewsFeed - 4 Jan 2007
Inspire Announces Dry Eye Program Update
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 Nov 2006
Inspire and FAES Farma Announce Licensing Agreement for New Oral Antihistamine to Target Allergy Market in United States and Canada
Biopharmaceuticals LIcensing
Return to NewsFeed  

 Additional items found! 27

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 27 additional stories matching:
RESTASIS
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.